Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-067 vs Lucentis in Neovascular AMD
NCT04667039Phase 3Recruiting
- Sponsor
- Generium
- Start
- Mar 2022
- Primary completion
- Aug 2024
- Modality
- Fab Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of GNR-067 in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Generium. Primary endpoint: Proportion of patients with an increase in BCVA score of 15 or more letters at Week 8. Started Mar 2022; status: recruiting.
02
Drugs
GNR-067
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04667039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667039.